Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,21632965,oral clearance,"The predicted oral clearance values of the drugs investigated ranged from 8.79 to 6320 l/h for tacrolimus and simvastatin, respectively, and were overall within 3-fold of the observed data with the exception of indinavir, atorvastatin, and buspirone.",Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632965/),[l] / [h],8.79 to 6320,1970,DB00490,Buspirone
,21632965,CLu(int),"The individual HJM CLu(int) values ranged from 17 to 14,000 μl · min(-1) · mg(-1) for atorvastatin and saquinavir, respectively, and corresponding interindividual variability in CLu(int) estimates ranged from 41 to 67%.",Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632965/),[μl] / [mg·min],"17 to 14,000",1971,DB00490,Buspirone
,21632965,F(G),"These in vitro data resulted in predicted F(G) values ranging from 0.03 to 0.94 for simvastatin and indinavir, respectively.",Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632965/),,0,1972,DB00490,Buspirone
,3285427,half-life,"Its main pharmacokinetic features are: complete absorption when given orally, short half-life (4 to 8 h), reduced plasma clearance in patients with hepatic cirrhosis or renal impairment and no major interaction with most of the other psychotropic drugs.",[Buspirone: pharmacological and clinical properties of the first member of a new anxiolytic drug family]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3285427/),h,4 to 8,3466,DB00490,Buspirone
,19660887,flow rate,As mobile phase a binary mixture of methanol (containing 0.1% formic acid)-water (containing 0.1% formic acid) was delivered by a Shimadzu LC-20AD pump in gradient mode at a flow rate of 0.4 ml/min in a run time of 5.0 min.,A sensitive LC-MS/MS method to quantify loureirin B in rat plasma with application to preclinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660887/),[ml] / [min],0.4,4136,DB00490,Buspirone
,19660887,run time,As mobile phase a binary mixture of methanol (containing 0.1% formic acid)-water (containing 0.1% formic acid) was delivered by a Shimadzu LC-20AD pump in gradient mode at a flow rate of 0.4 ml/min in a run time of 5.0 min.,A sensitive LC-MS/MS method to quantify loureirin B in rat plasma with application to preclinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660887/),min,5.0,4137,DB00490,Buspirone
,19660887,limit of detection,"The limit of detection and limit of quantification were 0.03 ng/ml and 0.08 ng/ml, respectively.",A sensitive LC-MS/MS method to quantify loureirin B in rat plasma with application to preclinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660887/),[ng] / [ml],0.03,4138,DB00490,Buspirone
,19660887,limit of quantification,"The limit of detection and limit of quantification were 0.03 ng/ml and 0.08 ng/ml, respectively.",A sensitive LC-MS/MS method to quantify loureirin B in rat plasma with application to preclinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660887/),[ng] / [ml],0.08,4139,DB00490,Buspirone
,19660887,tmax,"After oral administration of 16 g/kg longxuejie to rats, the main pharmacokinetic parameters tmax, Cmax, t(1/2), Ke and AUC(0-T) were 0.8 h, 7.99 microg/l, 1.94 l h, 0.365/h, and 22.21 microg h/l, respectively.",A sensitive LC-MS/MS method to quantify loureirin B in rat plasma with application to preclinical pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660887/),h,0.8,4140,DB00490,Buspirone
,19660887,AUC(0-T),"After oral administration of 16 g/kg longxuejie to rats, the main pharmacokinetic parameters tmax, Cmax, t(1/2), Ke and AUC(0-T) were 0.8 h, 7.99 microg/l, 1.94 l h, 0.365/h, and 22.21 microg h/l, respectively.",A sensitive LC-MS/MS method to quantify loureirin B in rat plasma with application to preclinical pharmacokinetic studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660887/),[h·μg] / [l],22.21,4141,DB00490,Buspirone
,26467669,flow rate,The flow rate was set at 0.50 mL/min.,Quantification and pharmacokinetics of crizotinib in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467669/),[ml] / [min],0.50,6324,DB00490,Buspirone
,26467669,m/z,The multiple reaction monitoring was based on the transitions of m/z = 450.3 → 177.1 for crizotinib and 386.2 → 122.2 for buspirone (IS).,Quantification and pharmacokinetics of crizotinib in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467669/),,450.3,6325,DB00490,Buspirone
,26467669,m/z,The multiple reaction monitoring was based on the transitions of m/z = 450.3 → 177.1 for crizotinib and 386.2 → 122.2 for buspirone (IS).,Quantification and pharmacokinetics of crizotinib in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467669/),,177.1,6326,DB00490,Buspirone
,26467669,m/z,The multiple reaction monitoring was based on the transitions of m/z = 450.3 → 177.1 for crizotinib and 386.2 → 122.2 for buspirone (IS).,Quantification and pharmacokinetics of crizotinib in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467669/),,386.2,6327,DB00490,Buspirone
,26467669,m/z,The multiple reaction monitoring was based on the transitions of m/z = 450.3 → 177.1 for crizotinib and 386.2 → 122.2 for buspirone (IS).,Quantification and pharmacokinetics of crizotinib in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467669/),,122.2,6328,DB00490,Buspirone
,26467669,oral absolute bioavailability,The oral absolute bioavailability of crizotinib in rats was 68.6 ± 9.63%.,Quantification and pharmacokinetics of crizotinib in rats by liquid chromatography-tandem mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467669/),%,68.6,6329,DB00490,Buspirone
,9578186,total area under the plasma buspirone concentration-time curve,"The total area under the plasma buspirone concentration-time curve after rifampicin was 10.4% (95% CI, 6.3-14.5%) of that after placebo (1.64+/-0.35 ng ml(-1) h vs 22.0+/-15.1 ng ml(-1) h (mean+/-s.d.); P< 0.01).",Concentrations and effects of buspirone are considerably reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[h·ng] / [ml],1.64,7058,DB00490,Buspirone
,9578186,total area under the plasma buspirone concentration-time curve,"The total area under the plasma buspirone concentration-time curve after rifampicin was 10.4% (95% CI, 6.3-14.5%) of that after placebo (1.64+/-0.35 ng ml(-1) h vs 22.0+/-15.1 ng ml(-1) h (mean+/-s.d.); P< 0.01).",Concentrations and effects of buspirone are considerably reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[h·ng] / [ml],22.0,7059,DB00490,Buspirone
,9578186,peak plasma concentration,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[ng] / [ml],6.6,7060,DB00490,Buspirone
,9578186,peak plasma concentration,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[ng] / [ml],0.84,7061,DB00490,Buspirone
,9578186,half-life,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),h,2.8,7062,DB00490,Buspirone
,9578186,half-life,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),h,1.3,7063,DB00490,Buspirone
,1362206,Plasma protein binding (free fraction),"Plasma protein binding (free fraction) for tandospirone was 30.4%, and for 1-PP, 87.5%.","Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362206/),%,30.4,7558,DB00490,Buspirone
,1362206,Plasma protein binding (free fraction),"Plasma protein binding (free fraction) for tandospirone was 30.4%, and for 1-PP, 87.5%.","Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362206/),%,87.5,7559,DB00490,Buspirone
,10365644,Recovery,"Recovery of buspirone and 1-PP averaged 98% and 89%, respectively, and the limit of quantification was 0.2 ng/mL for both compounds.",Determination of buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP) in human plasma by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365644/),%,98,13512,DB00490,Buspirone
,10365644,Recovery,"Recovery of buspirone and 1-PP averaged 98% and 89%, respectively, and the limit of quantification was 0.2 ng/mL for both compounds.",Determination of buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP) in human plasma by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365644/),%,89,13513,DB00490,Buspirone
,26031660,oral absolute bioavailability,"The oral absolute bioavailability of AST III was calculated to be 4.15 ± 0.67% with an elimination half-life value of 2.13 ± 0.11 h, suggesting its poor absorption and/or strong metabolism in vivo.",Determination of astragaloside III in rat plasma by liquid chromatography-tandem mass spectrometry and its application to a rat pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26031660/),%,4.15,17739,DB00490,Buspirone
,26031660,elimination half-life,"The oral absolute bioavailability of AST III was calculated to be 4.15 ± 0.67% with an elimination half-life value of 2.13 ± 0.11 h, suggesting its poor absorption and/or strong metabolism in vivo.",Determination of astragaloside III in rat plasma by liquid chromatography-tandem mass spectrometry and its application to a rat pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26031660/),h,2.13,17740,DB00490,Buspirone
,19591710,flow rate,The eluent was monitored by UV detector at 235 nm and at a flow rate of 1.0 mL min(-1).,Development of high performance liquid chromatography method for buspirone in rabbit serum: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19591710/),[ml] / [min],1.0,20067,DB00490,Buspirone
,12949996,maximum concentration (C(max)),"Mean maximum concentration (C(max)) was 6.1 ng/mL for gepirone-IR, which was statistically significantly (p < 0.05) higher than that of two of the ER-formulations (3.7 and 3.6 ng/mL, respectively, for types 2 and 3).",Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12949996/),[ng] / [ml],6.1,21704,DB00490,Buspirone
,12949996,maximum concentration (C(max)),"Mean maximum concentration (C(max)) was 6.1 ng/mL for gepirone-IR, which was statistically significantly (p < 0.05) higher than that of two of the ER-formulations (3.7 and 3.6 ng/mL, respectively, for types 2 and 3).",Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12949996/),[ng] / [ml],3.7,21705,DB00490,Buspirone
,12949996,maximum concentration (C(max)),"Mean maximum concentration (C(max)) was 6.1 ng/mL for gepirone-IR, which was statistically significantly (p < 0.05) higher than that of two of the ER-formulations (3.7 and 3.6 ng/mL, respectively, for types 2 and 3).",Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12949996/),[ng] / [ml],3.6,21706,DB00490,Buspirone
,12949996,time to C(max) (,The mean time to C(max) (mean T(max)) was 1.3 h for gepirone-IR and ranged from 4.8 to 5.6 h for gepirone-ER.,Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12949996/),h,1.3,21707,DB00490,Buspirone
,12949996,time to C(max) (,The mean time to C(max) (mean T(max)) was 1.3 h for gepirone-IR and ranged from 4.8 to 5.6 h for gepirone-ER.,Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12949996/),h,4.8 to 5.6,21708,DB00490,Buspirone
,11504277,bioavailability,"The bioavailability of buspirone from the ER formulation was more than three times higher than that from the IR formulation at steady state, and that of 1-PP was about 25% less.",A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504277/),%,25,23634,DB00490,Buspirone
,11504277,apparent half-life,The mean apparent half-life of buspirone from the ER formulation (9.04 hours) was considerably longer than that observed for the IR formulation (3.06 hours).,A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504277/),h,9.04,23635,DB00490,Buspirone
,11504277,apparent half-life,The mean apparent half-life of buspirone from the ER formulation (9.04 hours) was considerably longer than that observed for the IR formulation (3.06 hours).,A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504277/),h,3.06,23636,DB00490,Buspirone
,11504277,AUC ratio,The median 1-PP/buspirone AUC ratio was much higher for the IR formulation at steady state (24.4) than for the ER formulation (6.44).,A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504277/),,24.4,23637,DB00490,Buspirone
,11504277,AUC ratio,The median 1-PP/buspirone AUC ratio was much higher for the IR formulation at steady state (24.4) than for the ER formulation (6.44).,A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504277/),,6.44,23638,DB00490,Buspirone
,31520947,flow rate,"The six diterpene lactones, with the inclusion of two pairs of isomer (DIOB & D, DIOC & L), and Buspirone (internal standard, IS) were successfully separated using an XDB-C18 column with the gradient elution, consisting of water with 0.1% (v/v) FA and methanol with 0.1% (v/v) FA, under a flow rate of 0.50 mL/min in 5.8 min.",Development and application of a rapid and sensitive LC-MS/MS method for simultaneous quantification of six diterpene lactones in rats after oral administration of Rhizoma Dioscoreae Bulbiferae extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31520947/),[ml] / [min],0.50,36077,DB00490,Buspirone
,31520947,recovery,"No matrix effect and carry over was observed, and the recovery of the six analytes ranged from 87.3% to 109% with the RSD <11.4% within the concentrations range.",Development and application of a rapid and sensitive LC-MS/MS method for simultaneous quantification of six diterpene lactones in rats after oral administration of Rhizoma Dioscoreae Bulbiferae extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31520947/),%,87.3,36078,DB00490,Buspirone
,31520947,recovery,"No matrix effect and carry over was observed, and the recovery of the six analytes ranged from 87.3% to 109% with the RSD <11.4% within the concentrations range.",Development and application of a rapid and sensitive LC-MS/MS method for simultaneous quantification of six diterpene lactones in rats after oral administration of Rhizoma Dioscoreae Bulbiferae extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31520947/),%,109,36079,DB00490,Buspirone
,8930784,half-life (t1/2),"Significant changes in the pharmacokinetic parameters of haloperidol were not found in group I; a mean increase in the half-life (t1/2) of haloperidol from 21.5 to 28.1 hours was observed, but this finding was not statistically significant.",Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930784/),h,21.5,42408,DB00490,Buspirone
,8930784,half-life (t1/2),"Significant changes in the pharmacokinetic parameters of haloperidol were not found in group I; a mean increase in the half-life (t1/2) of haloperidol from 21.5 to 28.1 hours was observed, but this finding was not statistically significant.",Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930784/),h,28.1,42409,DB00490,Buspirone
,32608074,IC50,"Apatinib inhibited the generations of 1-PP and 6-OH buspirone dose-dependently with IC50 of 1.76 and 2.23 μm in RLMs, and 1.51 and 1.48 μm in HLMs, respectively.",The effect of apatinib on pharmacokinetic profile of buspirone both in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32608074/),μm,1.76,53180,DB00490,Buspirone
,32608074,IC50,"Apatinib inhibited the generations of 1-PP and 6-OH buspirone dose-dependently with IC50 of 1.76 and 2.23 μm in RLMs, and 1.51 and 1.48 μm in HLMs, respectively.",The effect of apatinib on pharmacokinetic profile of buspirone both in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32608074/),μm,2.23,53181,DB00490,Buspirone
,32608074,IC50,"Apatinib inhibited the generations of 1-PP and 6-OH buspirone dose-dependently with IC50 of 1.76 and 2.23 μm in RLMs, and 1.51 and 1.48 μm in HLMs, respectively.",The effect of apatinib on pharmacokinetic profile of buspirone both in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32608074/),μm,1.51,53182,DB00490,Buspirone
,32608074,IC50,"Apatinib inhibited the generations of 1-PP and 6-OH buspirone dose-dependently with IC50 of 1.76 and 2.23 μm in RLMs, and 1.51 and 1.48 μm in HLMs, respectively.",The effect of apatinib on pharmacokinetic profile of buspirone both in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32608074/),μm,1.48,53183,DB00490,Buspirone
,24274510,brain targeting efficiency,A high brain targeting efficiency (86.6%) and a direct nose to brain transport (88%) confirmed the direct nose to brain transport of buspirone following nasal administration of the microemulsions.,Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24274510/),%,86.6,59810,DB00490,Buspirone
,3370902,half-life (t 1/2),"When assessed between and during haemodialysis, the anuric patients had significantly (p less than 0.05) greater pharmacokinetic median values: half-life (t 1/2) = 15.2 vs 9.8 hours; area under the concentration-time curve (AUC) = 604 vs 404 nmol/L.h; and mean residence time (MRT) = 9.28 vs 6.96 hours.",Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370902/),h,15.2,63361,DB00490,Buspirone
,3370902,half-life (t 1/2),"When assessed between and during haemodialysis, the anuric patients had significantly (p less than 0.05) greater pharmacokinetic median values: half-life (t 1/2) = 15.2 vs 9.8 hours; area under the concentration-time curve (AUC) = 604 vs 404 nmol/L.h; and mean residence time (MRT) = 9.28 vs 6.96 hours.",Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370902/),h,9.8,63362,DB00490,Buspirone
,3370902,area under the concentration-time curve (AUC),"When assessed between and during haemodialysis, the anuric patients had significantly (p less than 0.05) greater pharmacokinetic median values: half-life (t 1/2) = 15.2 vs 9.8 hours; area under the concentration-time curve (AUC) = 604 vs 404 nmol/L.h; and mean residence time (MRT) = 9.28 vs 6.96 hours.",Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370902/),[nM] / [h·l],604,63363,DB00490,Buspirone
,3370902,area under the concentration-time curve (AUC),"When assessed between and during haemodialysis, the anuric patients had significantly (p less than 0.05) greater pharmacokinetic median values: half-life (t 1/2) = 15.2 vs 9.8 hours; area under the concentration-time curve (AUC) = 604 vs 404 nmol/L.h; and mean residence time (MRT) = 9.28 vs 6.96 hours.",Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370902/),[nM] / [h·l],404,63364,DB00490,Buspirone
,3370902,mean residence time (MRT),"When assessed between and during haemodialysis, the anuric patients had significantly (p less than 0.05) greater pharmacokinetic median values: half-life (t 1/2) = 15.2 vs 9.8 hours; area under the concentration-time curve (AUC) = 604 vs 404 nmol/L.h; and mean residence time (MRT) = 9.28 vs 6.96 hours.",Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370902/),h,9.28,63365,DB00490,Buspirone
,3370902,mean residence time (MRT),"When assessed between and during haemodialysis, the anuric patients had significantly (p less than 0.05) greater pharmacokinetic median values: half-life (t 1/2) = 15.2 vs 9.8 hours; area under the concentration-time curve (AUC) = 604 vs 404 nmol/L.h; and mean residence time (MRT) = 9.28 vs 6.96 hours.",Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370902/),h,6.96,63366,DB00490,Buspirone
,10193676,oral bioavailability,"Lignocaine is metabolized by cytochrome P450 3A4 enzyme (CYP3A4), and has a moderate to high extraction ratio resulting in oral bioavailability of 30%.",Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10193676/),%,30,66836,DB00490,Buspirone
,22651958,oral bioavailability (F),The oral bioavailability (F) of HJA was estimated to be 36.0±13.4% with an elimination half-life (t(1/2)) value of 1.04±0.20 h.,"LC-ESI-MS/MS analysis and pharmacokinetics of 6'-hydroxy justicidin A, a potential antitumor active component isolated from Justicia procumbens, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22651958/),%,36.0,69649,DB00490,Buspirone
,22651958,elimination half-life (t(1/2)),The oral bioavailability (F) of HJA was estimated to be 36.0±13.4% with an elimination half-life (t(1/2)) value of 1.04±0.20 h.,"LC-ESI-MS/MS analysis and pharmacokinetics of 6'-hydroxy justicidin A, a potential antitumor active component isolated from Justicia procumbens, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22651958/),h,1.04,69650,DB00490,Buspirone
,9805816,AUC,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[h·ng] / [ml],259.0,70275,DB00490,Buspirone
,9805816,AUC,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[h·ng] / [ml],326.7,70276,DB00490,Buspirone
,9805816,Cmax,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[ng] / [ml],34.5,70277,DB00490,Buspirone
,9805816,Cmax,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[ng] / [ml],74.3,70278,DB00490,Buspirone
,2964551,first component half-life,"Elimination of drug from the brain was biphasic, with a first component half-life of 24.8 min and a second component half-life of 96 min.",Pharmacokinetics of buspirone as determined by ex vivo (3H)-DPAT binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2964551/),min,24.8,73065,DB00490,Buspirone
,2964551,second component half-life,"Elimination of drug from the brain was biphasic, with a first component half-life of 24.8 min and a second component half-life of 96 min.",Pharmacokinetics of buspirone as determined by ex vivo (3H)-DPAT binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2964551/),min,96,73066,DB00490,Buspirone
,26966419,flow rate,"Liquid chromatograph separation was accomplished on a reverse-phase Kinetex XB-C18 column [50×4.6 mm; internal diameter: 2.6 μm (Phenomenex, Torrance, CA, U.S.A.)] with a gradient mobile phase of acetonitrile (0.05% formic acid, volume for volume) and water (0.05% formic acid) at a flow rate of 0.3 mL/min.",The ultra-performance liquid chromatography tandem mass spectrometry method for detection and quantification of C4NP in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966419/),[ml] / [min],0.3,85972,DB00490,Buspirone
,6151170,serum half-life,It achieves peak serum concentrations within one hour and has a serum half-life of 2 to 5 hours.,"Buspirone hydrochloride: a unique new anxiolytic agent. Pharmacokinetics, clinical pharmacology, abuse potential and clinical efficacy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6151170/),h,2 to 5,86750,DB00490,Buspirone
,3515929,systemic availability,The mean systemic availability is approximately 4 percent.,Metabolism and disposition of buspirone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),%,4,93421,DB00490,Buspirone
,3515929,Half-life,Half-life values observed in healthy volunteers ranged from two to 33 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,two to 33,93422,DB00490,Buspirone
,3515929,half-life,Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,2,93423,DB00490,Buspirone
,3515929,half-life,Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,11,93424,DB00490,Buspirone
,16638734,peak concentration,The peak concentration of buspirone averaged 1141 +/- 748 pg/mL with a time to maximum concentration of 0.8 hours.,Pharmacokinetics of buspirone in autistic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638734/),[pg] / [ml],1141,94450,DB00490,Buspirone
,16638734,time to maximum concentration,The peak concentration of buspirone averaged 1141 +/- 748 pg/mL with a time to maximum concentration of 0.8 hours.,Pharmacokinetics of buspirone in autistic children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638734/),h,0.8,94451,DB00490,Buspirone
,16638734,Half-life,Half-life was 1.6 +/- 0.3 hours.,Pharmacokinetics of buspirone in autistic children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638734/),h,1.6,94452,DB00490,Buspirone
,16638734,peak concentrations,Girls had higher peak concentrations (1876 vs 746 pg/mL) for buspirone and a lower peak 1-PP/buspirone concentration ratio.,Pharmacokinetics of buspirone in autistic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638734/),[pg] / [ml],1876,94453,DB00490,Buspirone
,16638734,peak concentrations,Girls had higher peak concentrations (1876 vs 746 pg/mL) for buspirone and a lower peak 1-PP/buspirone concentration ratio.,Pharmacokinetics of buspirone in autistic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638734/),[pg] / [ml],746,94454,DB00490,Buspirone
,2898533,Ki,"Several compounds demonstrated moderate to high affinity for the 5-HT1A receptor binding site; compounds 27 and 36 containing the serotonin mimetic (o-methoxyphenyl)piperazinyl moiety and compounds 42 and 50 containing the 2-pyrimidinylpiperazinyl moiety displayed the highest affinity, being equal to that of the 5-HT1A agonist 8-OH-DPAT (Ki = 1-1.3 nM).",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,1-1.3,99033,DB00490,Buspirone
,2898533,AB50,"Compound 34, 2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]hexahydro-4,7-etheno-1H- cyclobut[f]isoindole-1,3(2H)-dione, demonstrated 3 times the activity of buspirone, blocking CAR in rats with an AB50 of 13 mg/kg.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),[mg] / [kg],13,99034,DB00490,Buspirone
,2898533,Ki,"It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,16,99035,DB00490,Buspirone
,2898533,Ki,"It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,345,99036,DB00490,Buspirone
,2898533,Ki,"It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,458,99037,DB00490,Buspirone
,26980723,flow rate,"The analytes were chromatographed on a reverse-phase Agilent Zorbax XDB C18 column (2.1 mm × 50 mm, 3.5 μm) with a flow rate of 0.50 mL/min.",Development and Validation of a Sensitive and Specific LC-MS-MS Method for the Determination of Acotiamide in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26980723/),[ml] / [min],0.50,103937,DB00490,Buspirone
,26980723,precursor-product transitions (m/z),"The precursor-product transitions (m/z) in the positive ion mode were 451.4 → 271.3 and 386.2 → 122.2 for acotiamide and buspirone (internal standard, IS), respectively.",Development and Validation of a Sensitive and Specific LC-MS-MS Method for the Determination of Acotiamide in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26980723/),,451.4,103938,DB00490,Buspirone
,26980723,precursor-product transitions (m/z),"The precursor-product transitions (m/z) in the positive ion mode were 451.4 → 271.3 and 386.2 → 122.2 for acotiamide and buspirone (internal standard, IS), respectively.",Development and Validation of a Sensitive and Specific LC-MS-MS Method for the Determination of Acotiamide in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26980723/),,271.3,103939,DB00490,Buspirone
,26980723,precursor-product transitions (m/z),"The precursor-product transitions (m/z) in the positive ion mode were 451.4 → 271.3 and 386.2 → 122.2 for acotiamide and buspirone (internal standard, IS), respectively.",Development and Validation of a Sensitive and Specific LC-MS-MS Method for the Determination of Acotiamide in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26980723/),,386.2,103940,DB00490,Buspirone
,26980723,precursor-product transitions (m/z),"The precursor-product transitions (m/z) in the positive ion mode were 451.4 → 271.3 and 386.2 → 122.2 for acotiamide and buspirone (internal standard, IS), respectively.",Development and Validation of a Sensitive and Specific LC-MS-MS Method for the Determination of Acotiamide in Rat Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26980723/),,122.2,103941,DB00490,Buspirone
,26980723,oral absolute bioavailability (F),The oral absolute bioavailability (F) of acotiamide in rats was estimated to be 38.4 ± 13.5% with an elimination half-life (t1/2) value of 9.11 ± 0.40 h.,Development and Validation of a Sensitive and Specific LC-MS-MS Method for the Determination of Acotiamide in Rat Plasma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26980723/),%,38.4,103942,DB00490,Buspirone
,26980723,elimination half-life (t1/2),The oral absolute bioavailability (F) of acotiamide in rats was estimated to be 38.4 ± 13.5% with an elimination half-life (t1/2) value of 9.11 ± 0.40 h.,Development and Validation of a Sensitive and Specific LC-MS-MS Method for the Determination of Acotiamide in Rat Plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26980723/),h,9.11,103943,DB00490,Buspirone
,23108983,flow rate,"After simple one-step protein precipitation with methanol-acetonitrile (1:1, v/v), all three analytes were separated on an Agilent Zorbax SB-C(18) column using a gradient mobile phase consisting of water (0.1% formic acid)-acetonitrile (0.1% formic acid) at a flow rate of 0.50 mL/min.",Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108983/),[ml] / [min],0.50,112014,DB00490,Buspirone
,23108983,recoveries,The intra-day and inter-day precisions were all less than 15% and the accuracies were within the range of ±15%; recoveries were between 85.0 and 115%.,Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108983/),%,85.0 and 115,112015,DB00490,Buspirone
,27013798,half maximal inhibitory concentration,"In the in vitro CYP inhibition study, CUR inhibited the CYP3A-mediated metabolism of testosterone (TES) with a half maximal inhibitory concentration of 11.0 ± 3.3 μM.",Modulation of Hepatic Cytochrome P450 Enzymes by Curcumin and its Pharmacokinetic Consequences in Sprague-dawley Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27013798/),μM,11.0,114859,DB00490,Buspirone
,8033487,half-life,Peak plasma triazolam concentrations preceded maximum pharmacodynamic effects; the mean plasma effect site equilibration half-life was 9.4 minutes.,Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033487/),min,9.4,116162,DB00490,Buspirone
,20517714,flux,"BUSP-OPT (optimized formulation) showed a flux 104.6 microg cm(-2) h(-1), which could meet target flux.","Enhanced bioavailability of buspirone from reservoir-based transdermal therapeutic system, optimization of formulation employing Box-Behnken statistical design. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517714/),[μg] / [(cm)^2·h],104.6,116977,DB00490,Buspirone
,10411220,accumulation factor,The accumulation factor on day 7 for buspirone was nearly 5 for Cmax and 7 for AUC when compared with day 1.,Pharmacokinetics of buspirone following oral administration to rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10411220/),,5,117022,DB00490,Buspirone
,10411220,accumulation factor,The accumulation factor on day 7 for buspirone was nearly 5 for Cmax and 7 for AUC when compared with day 1.,Pharmacokinetics of buspirone following oral administration to rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10411220/),,7,117023,DB00490,Buspirone
,3689635,AUC,The mean AUC of buspirone was 55 +/- 38 s.d. ng ml-1 h in cirrhotics and 3.5 +/- 2.4 s.d. ng ml-1 h in normals.,Buspirone pharmacokinetics in patients with cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),[h·ng] / [ml],55,117589,DB00490,Buspirone
,3689635,AUC,The mean AUC of buspirone was 55 +/- 38 s.d. ng ml-1 h in cirrhotics and 3.5 +/- 2.4 s.d. ng ml-1 h in normals.,Buspirone pharmacokinetics in patients with cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),[h·ng] / [ml],3.5,117590,DB00490,Buspirone
,3689635,time until maximum concentration (tmax),"The time until maximum concentration (tmax) attained was similar in the two groups (0.6 vs 0.7 h), but mean maximum concentration Cmax was higher in patients (18.8 +/- 16.3 s.d. ng ml-1) than in normals (1.2 +/- 0.8 s.d. ng ml-1).",Buspirone pharmacokinetics in patients with cirrhosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),h,0.6,117591,DB00490,Buspirone
,3689635,time until maximum concentration (tmax),"The time until maximum concentration (tmax) attained was similar in the two groups (0.6 vs 0.7 h), but mean maximum concentration Cmax was higher in patients (18.8 +/- 16.3 s.d. ng ml-1) than in normals (1.2 +/- 0.8 s.d. ng ml-1).",Buspirone pharmacokinetics in patients with cirrhosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),h,0.7,117592,DB00490,Buspirone
,3689635,maximum concentration Cmax,"The time until maximum concentration (tmax) attained was similar in the two groups (0.6 vs 0.7 h), but mean maximum concentration Cmax was higher in patients (18.8 +/- 16.3 s.d. ng ml-1) than in normals (1.2 +/- 0.8 s.d. ng ml-1).",Buspirone pharmacokinetics in patients with cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),,18.8,117593,DB00490,Buspirone
,3689635,maximum concentration Cmax,"The time until maximum concentration (tmax) attained was similar in the two groups (0.6 vs 0.7 h), but mean maximum concentration Cmax was higher in patients (18.8 +/- 16.3 s.d. ng ml-1) than in normals (1.2 +/- 0.8 s.d. ng ml-1).",Buspirone pharmacokinetics in patients with cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),[ng] / [ml],1.2,117594,DB00490,Buspirone
,3689635,elimination half-life,"Mean elimination half-life of buspirone was greater in cirrhotics, but this difference was marginally significant statistically (cirrhotics, 6.1 +/- 3.5 s.d. h, normals 3.2 +/- 1.5 s.d. h, P = 0.05).",Buspirone pharmacokinetics in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),,6.1,117595,DB00490,Buspirone
,3689635,elimination half-life,"Mean elimination half-life of buspirone was greater in cirrhotics, but this difference was marginally significant statistically (cirrhotics, 6.1 +/- 3.5 s.d. h, normals 3.2 +/- 1.5 s.d. h, P = 0.05).",Buspirone pharmacokinetics in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),,3.2,117596,DB00490,Buspirone
,3689635,concentration,"In patients this occurred at 10.8 +/- 7.4 s.d. h after the dose, and its mean concentration was 3.1 +/- 6.6 ng ml-1.",Buspirone pharmacokinetics in patients with cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),[ng] / [ml],3.1,117597,DB00490,Buspirone
,3689635,concentration,In normal subjects the second peak occurred at 4.3 +/- 2.1 h after the dose and its mean concentration was 0.5 +/- 0.3 ng ml-1.,Buspirone pharmacokinetics in patients with cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),[ng] / [ml],0.5,117598,DB00490,Buspirone
,2874572,brain-to-plasma concentration ratios,"After oral administration of pharmacologically effective doses of BP-hydrochloride to rats (1 and 10 mg/kg), the metabolite appears in significant amounts in body fluids and tissues; it is highly concentrated in the central nervous system, the brain-to-plasma concentration ratios being approximately 5 at the time of the maximum concentrations (Cmax).",1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2874572/),,5,120626,DB00490,Buspirone
,19961912,C(max),"Pharmacokinetic data in rats following transdermal administration indicate that buspirone was present in plasma for 12 h, reaching a C(max) value of 120.07+/-86.97 ng/ml after 2 h.","Buspirone transdermal administration for menopausal syndromes, in vitro and in animal model studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961912/),[ng] / [ml],120.07,122591,DB00490,Buspirone
,19961912,F(rel),A F(rel) value of 0.89 was estimated for transdermal vs. oral buspirone.,"Buspirone transdermal administration for menopausal syndromes, in vitro and in animal model studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961912/),,0.89,122592,DB00490,Buspirone
,12438536,clearance,"Differences in the pharmacokinetics of buspirone and 1-PP were observed with values for clearance of 13.1 and 8.2 ml/min and for terminal elimination half-life of 25 and 79 min, respectively.",Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12438536/),[ml] / [min],13.1,135774,DB00490,Buspirone
,12438536,clearance,"Differences in the pharmacokinetics of buspirone and 1-PP were observed with values for clearance of 13.1 and 8.2 ml/min and for terminal elimination half-life of 25 and 79 min, respectively.",Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12438536/),[ml] / [min],8.2,135775,DB00490,Buspirone
,12438536,terminal elimination half-life,"Differences in the pharmacokinetics of buspirone and 1-PP were observed with values for clearance of 13.1 and 8.2 ml/min and for terminal elimination half-life of 25 and 79 min, respectively.",Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12438536/),min,25,135776,DB00490,Buspirone
,12438536,terminal elimination half-life,"Differences in the pharmacokinetics of buspirone and 1-PP were observed with values for clearance of 13.1 and 8.2 ml/min and for terminal elimination half-life of 25 and 79 min, respectively.",Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12438536/),min,79,135777,DB00490,Buspirone
,12438536,intrinsic activity,"Both buspirone and 1-PP behaved as partial agonists relative to R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin (R-8-OH-DPAT) with values of the intrinsic activity of 0.465 and 0.312, respectively.",Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12438536/),,0.465,135778,DB00490,Buspirone
,12438536,intrinsic activity,"Both buspirone and 1-PP behaved as partial agonists relative to R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin (R-8-OH-DPAT) with values of the intrinsic activity of 0.465 and 0.312, respectively.",Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12438536/),,0.312,135779,DB00490,Buspirone
,22934406,flow rate,"The separation was achieved using a C18 column (100 mm x 2.1 mm, 5 microm) with a mobile phase consisting of water-methanol-acetonitrile (69:8:23, v/v/v) containing 0.1% (v/v) formic acid at a flow rate of 0.2 mL/min.",[Determination of ilaprazole in beagle plasma and its pharmaeokineties by high performance liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22934406/),[ml] / [min],0.2,143717,DB00490,Buspirone
,22934406,recoveries,The mean recoveries at three spiked levels were about 106% and the matrix effects were less than 142.0%.,[Determination of ilaprazole in beagle plasma and its pharmaeokineties by high performance liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22934406/),%,106,143718,DB00490,Buspirone
,22934406,area under the plasma concentration-time curve (AUC(0-infinity),"The area under the plasma concentration-time curve (AUC(0-infinity) of ilaprazole after i.v. doses of 0.2, 0.8 and 3.2 mg/kg were (2.4 x 10(4) +/- 3 x 10(3)), (8.8 x 10(4) +/- 1.6 x 10(4)) and (5.4 x 10(5) +/- 8 x 10(4)) microg/L x min, respectively.",[Determination of ilaprazole in beagle plasma and its pharmaeokineties by high performance liquid chromatography-mass spectrometry]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22934406/),[μg] / [l·min],2.4 x 10(4),143719,DB00490,Buspirone
,22934406,area under the plasma concentration-time curve (AUC(0-infinity),"The area under the plasma concentration-time curve (AUC(0-infinity) of ilaprazole after i.v. doses of 0.2, 0.8 and 3.2 mg/kg were (2.4 x 10(4) +/- 3 x 10(3)), (8.8 x 10(4) +/- 1.6 x 10(4)) and (5.4 x 10(5) +/- 8 x 10(4)) microg/L x min, respectively.",[Determination of ilaprazole in beagle plasma and its pharmaeokineties by high performance liquid chromatography-mass spectrometry]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22934406/),[μg] / [l·min],8.8 x 10(4),143720,DB00490,Buspirone
,22934406,area under the plasma concentration-time curve (AUC(0-infinity),"The area under the plasma concentration-time curve (AUC(0-infinity) of ilaprazole after i.v. doses of 0.2, 0.8 and 3.2 mg/kg were (2.4 x 10(4) +/- 3 x 10(3)), (8.8 x 10(4) +/- 1.6 x 10(4)) and (5.4 x 10(5) +/- 8 x 10(4)) microg/L x min, respectively.",[Determination of ilaprazole in beagle plasma and its pharmaeokineties by high performance liquid chromatography-mass spectrometry]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22934406/),[μg] / [l·min],5.4 x 10(5,143721,DB00490,Buspirone
,24710899,IC50,"In the in vitro cytochrome P450 inhibition study, the rate of disappearance of testosterone was significantly reduced in the presence of 10 µM PU, while that of other cytochrome P450 substrates was not significantly affected in both human and rat liver microsomes, suggesting that puerarin inhibits the in vitro hepatic CYP3A-mediated metabolism in the human and rat systems (IC50 = 15.5 ± 3.9 µM).",In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710899/),μM,15.5,150775,DB00490,Buspirone
,8103528,Cmax,"The mean gepirone Cmax was 16.98 +/- 8.12 ng/mL (fed) and 18.73 +/- 10.30 ng/mL (fasted), with mean t1/2 of 3.32 +/- 1.84 hours (fed) and 2.94 +/- 0.90 hours (fasted).",Effect of food on the bioavailability of gepirone in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),[ng] / [ml],16.98,160766,DB00490,Buspirone
,8103528,Cmax,"The mean gepirone Cmax was 16.98 +/- 8.12 ng/mL (fed) and 18.73 +/- 10.30 ng/mL (fasted), with mean t1/2 of 3.32 +/- 1.84 hours (fed) and 2.94 +/- 0.90 hours (fasted).",Effect of food on the bioavailability of gepirone in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),[ng] / [ml],18.73,160767,DB00490,Buspirone
,8103528,t1/2,"The mean gepirone Cmax was 16.98 +/- 8.12 ng/mL (fed) and 18.73 +/- 10.30 ng/mL (fasted), with mean t1/2 of 3.32 +/- 1.84 hours (fed) and 2.94 +/- 0.90 hours (fasted).",Effect of food on the bioavailability of gepirone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,3.32,160768,DB00490,Buspirone
,8103528,t1/2,"The mean gepirone Cmax was 16.98 +/- 8.12 ng/mL (fed) and 18.73 +/- 10.30 ng/mL (fasted), with mean t1/2 of 3.32 +/- 1.84 hours (fed) and 2.94 +/- 0.90 hours (fasted).",Effect of food on the bioavailability of gepirone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,2.94,160769,DB00490,Buspirone
,8103528,area under the curveinf (AUCinf),"Food significantly increased the mean area under the curveinf (AUCinf) from 55.26 +/- 35.74 ng.hour/mL (fasted) to 75.69 +/- 42.79 ng.hour/mL (fed), and the mean residence timeinf (MRTinf) from 4.31 +/- 0.78 hours (fasted) to 5.37 +/- 1.21 hours (fed).",Effect of food on the bioavailability of gepirone in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),[h·ng] / [ml],55.26,160770,DB00490,Buspirone
,8103528,area under the curveinf (AUCinf),"Food significantly increased the mean area under the curveinf (AUCinf) from 55.26 +/- 35.74 ng.hour/mL (fasted) to 75.69 +/- 42.79 ng.hour/mL (fed), and the mean residence timeinf (MRTinf) from 4.31 +/- 0.78 hours (fasted) to 5.37 +/- 1.21 hours (fed).",Effect of food on the bioavailability of gepirone in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),[h·ng] / [ml],75.69,160771,DB00490,Buspirone
,8103528,mean residence timeinf (MRTinf),"Food significantly increased the mean area under the curveinf (AUCinf) from 55.26 +/- 35.74 ng.hour/mL (fasted) to 75.69 +/- 42.79 ng.hour/mL (fed), and the mean residence timeinf (MRTinf) from 4.31 +/- 0.78 hours (fasted) to 5.37 +/- 1.21 hours (fed).",Effect of food on the bioavailability of gepirone in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,4.31,160772,DB00490,Buspirone
,8103528,mean residence timeinf (MRTinf),"Food significantly increased the mean area under the curveinf (AUCinf) from 55.26 +/- 35.74 ng.hour/mL (fasted) to 75.69 +/- 42.79 ng.hour/mL (fed), and the mean residence timeinf (MRTinf) from 4.31 +/- 0.78 hours (fasted) to 5.37 +/- 1.21 hours (fed).",Effect of food on the bioavailability of gepirone in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,5.37,160773,DB00490,Buspirone
,8103528,time to maximum plasma concentration (tmax),"The median time to maximum plasma concentration (tmax) for gepirone was also significantly increased in the presence of food, 2.0 hours, versus 0.75 hours in the absence of food.",Effect of food on the bioavailability of gepirone in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,2.0,160774,DB00490,Buspirone
,8103528,time to maximum plasma concentration (tmax),"The median time to maximum plasma concentration (tmax) for gepirone was also significantly increased in the presence of food, 2.0 hours, versus 0.75 hours in the absence of food.",Effect of food on the bioavailability of gepirone in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,0.75,160775,DB00490,Buspirone
,8103528,t1/2,"Mean t1/2 for 1-PP in the presence and absence of food was 6.06 +/- 1.75 and 5.76 +/- 1.75 hours, respectively.",Effect of food on the bioavailability of gepirone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,6.06,160776,DB00490,Buspirone
,8103528,t1/2,"Mean t1/2 for 1-PP in the presence and absence of food was 6.06 +/- 1.75 and 5.76 +/- 1.75 hours, respectively.",Effect of food on the bioavailability of gepirone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,5.76,160777,DB00490,Buspirone
,8103528,MRTinf,"MRTinf, however, was increased significantly from 9.32 +/- 2.68 hours (fasted) to 10.53 +/- 2.89 hours (fed).",Effect of food on the bioavailability of gepirone in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,9.32,160778,DB00490,Buspirone
,8103528,MRTinf,"MRTinf, however, was increased significantly from 9.32 +/- 2.68 hours (fasted) to 10.53 +/- 2.89 hours (fed).",Effect of food on the bioavailability of gepirone in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,10.53,160779,DB00490,Buspirone
,32078103,fraction absorbed,The in vivo contribution of P-gp is minimal for high permeable compounds owing to their fraction absorbed of nearly 1.0.,"Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078103/),,1.0,161619,DB00490,Buspirone
,10320950,peak plasma concentration (Cmax),"The mean peak plasma concentration (Cmax) is approximately 2.5 micrograms/L, and the time to reach the peak is under 1 hour.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[μg] / [l],2.5,183615,DB00490,Buspirone
under,10320950,time to reach the peak,"The mean peak plasma concentration (Cmax) is approximately 2.5 micrograms/L, and the time to reach the peak is under 1 hour.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),h,1,183616,DB00490,Buspirone
,10320950,absolute bioavailability,The absolute bioavailability of buspirone is approximately 4%.,"Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),%,4,183617,DB00490,Buspirone
,10320950,volume of distribution,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[l] / [kg],5.3,183618,DB00490,Buspirone
,10320950,systemic clearance,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[l] / [h·kg],1.7,183619,DB00490,Buspirone
,10320950,elimination half-life,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),h,2.5,183620,DB00490,Buspirone
,7619663,critical flicker fusion threshold,"4. Only buspirone reduced total reaction time and increased critical flicker fusion threshold measured 12 h after the evening dose and these effects were correlated with the residual plasma 1PP concentration which was higher on buspirone than on ipsapirone (2.76 micrograms l-1, 95% CI:1.3-4.22 vs 0.65 microgram l-1, 95% CI: 0.32-0.98, P = 0.006).",Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619663/),[μg] / [l],2.76,188197,DB00490,Buspirone
,7619663,AUC ipsapirone/AUC 1PP ratio,The AUC ipsapirone/AUC 1PP ratio was 6.45 and the AUC buspirone/AUC 1PP ratio was 0.076.,Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619663/),,6.45,188198,DB00490,Buspirone
,7619663,AUC buspirone/AUC 1PP ratio,The AUC ipsapirone/AUC 1PP ratio was 6.45 and the AUC buspirone/AUC 1PP ratio was 0.076.,Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619663/),,0.076,188199,DB00490,Buspirone
,9542119,absolute recovery,The compounds were isolated from plasma on a Bakerbond C18 solid-phase extraction cartridge and the mean absolute recovery was 92.9%.,"Validated liquid chromatographic method for the determination of N-3-(2,2,5,5-tetramethyl-3-pirrolin-3-carboxamidopropylphthalimide hydrochloride), a novel antiarrhythmic agent in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542119/),%,92.9,189723,DB00490,Buspirone
,26010440,IC50,"Moreover, GLY inhibited CYP3A activity with an IC50 of 20.1 ± 10.7 μM via a mixed inhibition mechanism.",Modulation of Cytochrome P450 Activity by 18β-Glycyrrhetic Acid and its Consequence on Buspirone Pharmacokinetics in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26010440/),μM,20.1,201440,DB00490,Buspirone
,31317804,kobs,These findings were supported by the result that the kobs (0.00000118 min-1) of bergamottin for CYP3A was lower than the kdeg (0.0005 min-1) for CYP3A.,Bergamottin can be used to assess CYP3A-mediated intestinal first-pass metabolism without affecting P-glycoprotein-mediated efflux in rats. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31317804/),1/[min],0.00000118,205759,DB00490,Buspirone
,31317804,kdeg,These findings were supported by the result that the kobs (0.00000118 min-1) of bergamottin for CYP3A was lower than the kdeg (0.0005 min-1) for CYP3A.,Bergamottin can be used to assess CYP3A-mediated intestinal first-pass metabolism without affecting P-glycoprotein-mediated efflux in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31317804/),1/[min],0.0005,205760,DB00490,Buspirone
,23873286,IC50,"Prior to in vivo studies, ketoconazole and ritonavir were shown to inhibit midazolam hydroxylation with IC50 values of 350 ± 60 nm and 11 ± 3 nm, respectively, in rat liver microsomes (RLM).",Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873286/),nm,350,206834,DB00490,Buspirone
,23873286,IC50,"Prior to in vivo studies, ketoconazole and ritonavir were shown to inhibit midazolam hydroxylation with IC50 values of 350 ± 60 nm and 11 ± 3 nm, respectively, in rat liver microsomes (RLM).",Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873286/),nm,11,206835,DB00490,Buspirone
,6613160,t1/2 (beta),"After i.v. injection (10 mg/kg) to rats, buspirone is rapidly cleared from blood with a t1/2 (beta) or 30 min.",Disposition and metabolism of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6613160/),min,30,208745,DB00490,Buspirone
,30822365,total flow rate,"These analytes and the internal standards were extracted from plasma using protein precipitation with acetonitrile, then separated on a CAPCELL PAK ADME C18 column using a mobile phase of acetonitrile and 5 mm ammonium formate acidified with formic acid (0.1%, v/v) at a total flow rate of 0.4 mL/min.","Simultaneous determination of tandospirone and its active metabolite, 1-[2-pyrimidyl]-piperazine in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30822365/),[ml] / [min],0.4,214288,DB00490,Buspirone
,30822365,Total time,Total time for each chromatograph was 3.0 min.,"Simultaneous determination of tandospirone and its active metabolite, 1-[2-pyrimidyl]-piperazine in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30822365/),min,3.0,214289,DB00490,Buspirone
,17494642,plasma clearance,"The plasma clearance (47.3 +/- 3.5 ml/min/kg), volume of distribution (2.6 +/- 0.3 l/kg), and half-life (1.2 +/- 0.2 h) of 6-OH-buspirone in rats were similar to those for buspirone.",6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),[ml] / [kg·min],47.3,215700,DB00490,Buspirone
,17494642,volume of distribution,"The plasma clearance (47.3 +/- 3.5 ml/min/kg), volume of distribution (2.6 +/- 0.3 l/kg), and half-life (1.2 +/- 0.2 h) of 6-OH-buspirone in rats were similar to those for buspirone.",6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),[l] / [kg],2.6,215701,DB00490,Buspirone
,17494642,half-life,"The plasma clearance (47.3 +/- 3.5 ml/min/kg), volume of distribution (2.6 +/- 0.3 l/kg), and half-life (1.2 +/- 0.2 h) of 6-OH-buspirone in rats were similar to those for buspirone.",6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),h,1.2,215702,DB00490,Buspirone
,17494642,Bioavailability,Bioavailability was higher for 6-OH-buspirone (19%) compared with that for buspirone (1.4%).,6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),%,19,215703,DB00490,Buspirone
,17494642,Bioavailability,Bioavailability was higher for 6-OH-buspirone (19%) compared with that for buspirone (1.4%).,6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),%,1.4,215704,DB00490,Buspirone
,17494642,EC(50),"After intravenous infusions to steady-state levels in plasma, 6-OH-buspirone and buspirone increased 5-hydroxytryptamine (HT)(1A) receptor occupancy in a concentration-dependent manner with EC(50) values of 1.0 +/- 0.3 and 0.38 +/- 0.06 microM in the dorsal raphe and 4.0 +/- 0.6 and 1.5 +/- 0.3 microM in the hippocampus, respectively.",6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),μM,1.0,215705,DB00490,Buspirone
,17494642,EC(50),"After intravenous infusions to steady-state levels in plasma, 6-OH-buspirone and buspirone increased 5-hydroxytryptamine (HT)(1A) receptor occupancy in a concentration-dependent manner with EC(50) values of 1.0 +/- 0.3 and 0.38 +/- 0.06 microM in the dorsal raphe and 4.0 +/- 0.6 and 1.5 +/- 0.3 microM in the hippocampus, respectively.",6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),μM,0.38,215706,DB00490,Buspirone
,17494642,EC(50),"After intravenous infusions to steady-state levels in plasma, 6-OH-buspirone and buspirone increased 5-hydroxytryptamine (HT)(1A) receptor occupancy in a concentration-dependent manner with EC(50) values of 1.0 +/- 0.3 and 0.38 +/- 0.06 microM in the dorsal raphe and 4.0 +/- 0.6 and 1.5 +/- 0.3 microM in the hippocampus, respectively.",6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),μM,4.0,215707,DB00490,Buspirone
,17494642,EC(50),"After intravenous infusions to steady-state levels in plasma, 6-OH-buspirone and buspirone increased 5-hydroxytryptamine (HT)(1A) receptor occupancy in a concentration-dependent manner with EC(50) values of 1.0 +/- 0.3 and 0.38 +/- 0.06 microM in the dorsal raphe and 4.0 +/- 0.6 and 1.5 +/- 0.3 microM in the hippocampus, respectively.",6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),μM,1.5,215708,DB00490,Buspirone
,22014654,flow rate,"Atractylenolide I and I.S. were separated on a Phenomenex Gemini C(18) column (50 mm × 2.0 mm, 5 μm) with gradient mobile phase at the flow rate of 0.4 ml/min.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),[ml] / [min],0.4,220143,DB00490,Buspirone
,22014654,limit of detection (LOD),"The limit of detection (LOD) and the limit of quantification (LOQ) were 0.6 ng/ml and 2.0 ng/ml, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),[ng] / [ml],0.6,220144,DB00490,Buspirone
,22014654,limit of quantification (LOQ),"The limit of detection (LOD) and the limit of quantification (LOQ) were 0.6 ng/ml and 2.0 ng/ml, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),[ng] / [ml],2.0,220145,DB00490,Buspirone
,22014654,recoveries,"The recoveries of atractylenolide I and I.S. were 91.4% and 87.8%, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),%,91.4,220146,DB00490,Buspirone
,22014654,recoveries,"The recoveries of atractylenolide I and I.S. were 91.4% and 87.8%, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),%,87.8,220147,DB00490,Buspirone
,22014654,T(max),"The main pharmacokinetic parameters T(max) (the time to peak), C(max) (the concentration to peak), T(0.5) (the biological half time), and K(e) (the elimination rate constant) were 0.81 ± 0.11h, 7.99 ± 1.2 ng/ml, 1.94 ± 0.27 h, 0.365 ± 0.06/h, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),h,0.81,220148,DB00490,Buspirone
,22014654,C(max),"The main pharmacokinetic parameters T(max) (the time to peak), C(max) (the concentration to peak), T(0.5) (the biological half time), and K(e) (the elimination rate constant) were 0.81 ± 0.11h, 7.99 ± 1.2 ng/ml, 1.94 ± 0.27 h, 0.365 ± 0.06/h, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),[ng] / [ml],7.99,220149,DB00490,Buspirone
,22014654,C(max),"The main pharmacokinetic parameters T(max) (the time to peak), C(max) (the concentration to peak), T(0.5) (the biological half time), and K(e) (the elimination rate constant) were 0.81 ± 0.11h, 7.99 ± 1.2 ng/ml, 1.94 ± 0.27 h, 0.365 ± 0.06/h, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),h,1.94,220150,DB00490,Buspirone
,22014654,T(0.5),"The main pharmacokinetic parameters T(max) (the time to peak), C(max) (the concentration to peak), T(0.5) (the biological half time), and K(e) (the elimination rate constant) were 0.81 ± 0.11h, 7.99 ± 1.2 ng/ml, 1.94 ± 0.27 h, 0.365 ± 0.06/h, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),[ng] / [ml],7.99,220151,DB00490,Buspirone
,22014654,biological half time,"The main pharmacokinetic parameters T(max) (the time to peak), C(max) (the concentration to peak), T(0.5) (the biological half time), and K(e) (the elimination rate constant) were 0.81 ± 0.11h, 7.99 ± 1.2 ng/ml, 1.94 ± 0.27 h, 0.365 ± 0.06/h, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),[ng] / [ml],7.99,220152,DB00490,Buspirone
,22014654,K(e),"The main pharmacokinetic parameters T(max) (the time to peak), C(max) (the concentration to peak), T(0.5) (the biological half time), and K(e) (the elimination rate constant) were 0.81 ± 0.11h, 7.99 ± 1.2 ng/ml, 1.94 ± 0.27 h, 0.365 ± 0.06/h, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),[ng] / [ml],7.99,220153,DB00490,Buspirone
,22014654,K(e),"The main pharmacokinetic parameters T(max) (the time to peak), C(max) (the concentration to peak), T(0.5) (the biological half time), and K(e) (the elimination rate constant) were 0.81 ± 0.11h, 7.99 ± 1.2 ng/ml, 1.94 ± 0.27 h, 0.365 ± 0.06/h, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),h,1.94,220154,DB00490,Buspirone
,27803469,flow rate,Chromatographic separation was performed using Kinetex® C8 column with an isocratic mobile phase consisting of acetonitrile and 10-mM potassium phosphate buffer (pH 6.0) at a flow rate of 1.0 mL/min.,Development of HPLC Method for the Determination of Buspirone in Rat Plasma Using Fluorescence Detection and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27803469/),[ml] / [min],1.0,222616,DB00490,Buspirone
,27803469,limit of detection,"The linearity was established at 20.0-5000 ng/mL, and the limit of detection was 6.51 ng/mL.",Development of HPLC Method for the Determination of Buspirone in Rat Plasma Using Fluorescence Detection and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27803469/),[ng] / [ml],6.51,222617,DB00490,Buspirone
,23420017,Tmax,"The main pharmacokinetic parameters Tmax, Cmax, T1/2, and Ke were 1.88±0.22h, 18.0±3.1ng/ml, 6.89±1.0h and 0.103±0.01l/h, respectively.",Determination of diosbulbin B in rat plasma and urine by LC-MS/MS and its application in pharmacokinetic and urinary excretion studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23420017/),h,1.88,222768,DB00490,Buspirone
,23420017,Ke,"The main pharmacokinetic parameters Tmax, Cmax, T1/2, and Ke were 1.88±0.22h, 18.0±3.1ng/ml, 6.89±1.0h and 0.103±0.01l/h, respectively.",Determination of diosbulbin B in rat plasma and urine by LC-MS/MS and its application in pharmacokinetic and urinary excretion studies. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23420017/),[l] / [h],0.103,222769,DB00490,Buspirone
,23420017,cumulative excretion,"A cumulative excretion of disobulbin B in rat urine was 2.69±0.43μg at 60h after dosing, accounting for 0.89% of the total dose.",Determination of diosbulbin B in rat plasma and urine by LC-MS/MS and its application in pharmacokinetic and urinary excretion studies. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23420017/),μg,2.69,222770,DB00490,Buspirone
,22831883,flow rate,Elution was achieved with a gradient mobile phase consisting of water and acetonitrile both containing 0.1% formic acid at a flow rate of 0.40 mL/min.,Application of a sensitive and specific LC-MS/MS method for determination of chinensinaphthol methyl ether in rat plasma for a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831883/),[ml] / [min],0.40,226775,DB00490,Buspirone
,22831883,precursor/product transitions (m/z),"The precursor/product transitions (m/z) in the positive ion mode were 394.5→346.0 and 386.1→122.0 for CME and IS, respectively.",Application of a sensitive and specific LC-MS/MS method for determination of chinensinaphthol methyl ether in rat plasma for a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831883/),,394.5,226776,DB00490,Buspirone
,22831883,precursor/product transitions (m/z),"The precursor/product transitions (m/z) in the positive ion mode were 394.5→346.0 and 386.1→122.0 for CME and IS, respectively.",Application of a sensitive and specific LC-MS/MS method for determination of chinensinaphthol methyl ether in rat plasma for a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831883/),,346.0,226777,DB00490,Buspirone
,22831883,precursor/product transitions (m/z),"The precursor/product transitions (m/z) in the positive ion mode were 394.5→346.0 and 386.1→122.0 for CME and IS, respectively.",Application of a sensitive and specific LC-MS/MS method for determination of chinensinaphthol methyl ether in rat plasma for a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831883/),,386.1,226778,DB00490,Buspirone
,22831883,precursor/product transitions (m/z),"The precursor/product transitions (m/z) in the positive ion mode were 394.5→346.0 and 386.1→122.0 for CME and IS, respectively.",Application of a sensitive and specific LC-MS/MS method for determination of chinensinaphthol methyl ether in rat plasma for a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831883/),,122.0,226779,DB00490,Buspirone
,22831883,oral absolute bioavailability (F),"The oral absolute bioavailability (F) of CME was estimated to be 3.2±0.2% with an elimination half-life (t½) value of 2.4±0.8h, suggesting its poor absorption and/or strong metabolism in vivo.",Application of a sensitive and specific LC-MS/MS method for determination of chinensinaphthol methyl ether in rat plasma for a bioavailability study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831883/),%,3.2,226780,DB00490,Buspirone
,22831883,elimination half-life (t½),"The oral absolute bioavailability (F) of CME was estimated to be 3.2±0.2% with an elimination half-life (t½) value of 2.4±0.8h, suggesting its poor absorption and/or strong metabolism in vivo.",Application of a sensitive and specific LC-MS/MS method for determination of chinensinaphthol methyl ether in rat plasma for a bioavailability study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831883/),h,2.4,226781,DB00490,Buspirone
,22877221,turnaround time,"The approach allows for the investigation of a set of six compounds simultaneously, with a turnaround time of 1 week or less.",A semi-automated method for the integrated evaluation of half-life and metabolic soft spots of discovery compounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22877221/),week,1,231407,DB00490,Buspirone
,9098985,flow-rate,"pH 3.0, adjusted with orthophosphoric acids at a flow-rate of 0.06 ml/min.",Measurement and pharmacokinetic analysis of buspirone by means of brain microdialysis coupled to high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098985/),[ml] / [min],0.06,232949,DB00490,Buspirone
,11293269,absolute extraction recovery,The absolute extraction recovery from plasma samples was 76%.,High-performance liquid chromatographic analysis for the determination of buspirone analogue--mesmar in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11293269/),%,76,233875,DB00490,Buspirone
,19406007,absolute bioavailability,The nasal Bus-chitosan formulation improved the absolute bioavailability to 61% and the plasma concentration peaked at 30 min whereas the peak for nasal Bus-plain formulation was 60 min.,Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406007/),%,61,253422,DB00490,Buspirone
,19406007,AUC0-480,The AUC0-480 in brain after nasal administration of Bus-chitosan formulation was 2.5 times that obtained by intravenous administration (711+/-252 ng/g vs 282+/-110 ng/g); this was also considerably higher than that obtained with the intranasal Bus-plain formulation (354+/-80 ng/g).,Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406007/),[ng] / [g],711,253423,DB00490,Buspirone
,19406007,AUC0-480,The AUC0-480 in brain after nasal administration of Bus-chitosan formulation was 2.5 times that obtained by intravenous administration (711+/-252 ng/g vs 282+/-110 ng/g); this was also considerably higher than that obtained with the intranasal Bus-plain formulation (354+/-80 ng/g).,Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406007/),[ng] / [g],282,253424,DB00490,Buspirone
,19406007,AUC0-480,The AUC0-480 in brain after nasal administration of Bus-chitosan formulation was 2.5 times that obtained by intravenous administration (711+/-252 ng/g vs 282+/-110 ng/g); this was also considerably higher than that obtained with the intranasal Bus-plain formulation (354+/-80 ng/g).,Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406007/),[ng] / [g],354,253425,DB00490,Buspirone
>,19406007,drug targeting index,The high percentage of direct drug transport to the brain (75.77%) and high drug targeting index (>1) confirmed the direct nose to brain transport of buspirone following nasal administration of Bus-chitosan formulation.,Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406007/),,1,253426,DB00490,Buspirone
,9871430,time of the peak concentration (tmax),"The time of the peak concentration (tmax) of buspirone increased from 0.75 to 3 hours (P < .01), and the elimination half-life (t1/2) was slightly increased (P < .01) by grapefruit juice.",Grapefruit juice substantially increases plasma concentrations of buspirone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871430/),h,0.75,255681,DB00490,Buspirone
,9871430,time of the peak concentration (tmax),"The time of the peak concentration (tmax) of buspirone increased from 0.75 to 3 hours (P < .01), and the elimination half-life (t1/2) was slightly increased (P < .01) by grapefruit juice.",Grapefruit juice substantially increases plasma concentrations of buspirone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871430/),h,3,255682,DB00490,Buspirone
,22706921,flow rate,"Chromatographic separation was successfully achieved on an Agilent Zorbax-C(18) column (2.1 × 50 mm, 3.5 µm) with a flow rate of 0.40 mL/min.",Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706921/),[ml] / [min],0.40,257743,DB00490,Buspirone
,22706921,m/z,The multiple reaction monitoring was based on the transitions of m/z = 379.1 → 320.1 for TEME and 386.1 → 122.0 for buspirone (internal standard).,Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706921/),,379.1,257744,DB00490,Buspirone
,22706921,m/z,The multiple reaction monitoring was based on the transitions of m/z = 379.1 → 320.1 for TEME and 386.1 → 122.0 for buspirone (internal standard).,Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706921/),,320.1,257745,DB00490,Buspirone
,22706921,m/z,The multiple reaction monitoring was based on the transitions of m/z = 379.1 → 320.1 for TEME and 386.1 → 122.0 for buspirone (internal standard).,Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706921/),,386.1,257746,DB00490,Buspirone
,22706921,m/z,The multiple reaction monitoring was based on the transitions of m/z = 379.1 → 320.1 for TEME and 386.1 → 122.0 for buspirone (internal standard).,Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706921/),,122.0,257747,DB00490,Buspirone
,22706921,oral absolute bioavailability,"The oral absolute bioavailability of TEME was estimated to be 5.85 ± 1.41% with an elimination half-life value of 2.61 ± 0.55 h, suggesting its poor absorption and/or strong metabolism in vivo.",Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706921/),%,5.85,257748,DB00490,Buspirone
,22706921,elimination half-life,"The oral absolute bioavailability of TEME was estimated to be 5.85 ± 1.41% with an elimination half-life value of 2.61 ± 0.55 h, suggesting its poor absorption and/or strong metabolism in vivo.",Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706921/),h,2.61,257749,DB00490,Buspirone
